Biomarcadores en el pronóstico del embolismo pulmonar agudo
Biomarcadores en el pronóstico del embolismo pulmonar agudo
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Mostrar biografía de los autores
La embolía pulmonar aguda es una enfermedad con una amplia distribución dentro de la población general, con impacto importante en la morbi-mortalidad de los pacientes y con un espectro clínico variable, terapias médicas como la anticoagulación, el uso de fibrinolíticos han disminuido de manera ostensible la mortalidad de los pacientes en el transcurso de las últimas décadas; sin embargo, por tratarse de una entidad de diagnóstico complicado es importante el refinamiento de métodos diagnósticos prácticos, rápidos y confiables que nos permitan el diseño de estrategias terapéuticas para impactar favorablemente en los desenlaces adversos derivados de esta enfermedad.
Visitas del artículo 32 | Visitas PDF 156
Descargas
- Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-5.
- Beasley R, Raymond N, Hill S, Nowitz M, Hughes R. eThrombosis: the 21st century variant of venous thromboembolism associated with immobility. Eur Respir J 2003; 21: 374-6.
- Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18: 353-72.
- Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
- Heit JA, Cohen AT, Anderson FA, VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the U. S. Blood 2005; 106: 267a.
- Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol 2004; 93: 1197-9.
- Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of lifethreatening pulmonary embolism. Br Med J 1974; 1: 343-7.
- Levine M, Hirsh J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-9.
- Dalla-Volta S, Palla A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20: 520-6.
- Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006; 97: 1386-90.
- Kostrubiec M, Pruszczyk P, Bochowicz A, Pacho R, Szulc M, Kaczynska A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-72.
- Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116: 427-33.
- Kruger S, Merx MW, Graf J. Utility of brain natriuretic peptide to predict right ventricular dysfunction and clinical outcome in patients with acute pulmonary embolism. Circulation 2003; 108: e94-5.
- Pruszczyk P, Kostrubiec M, Bochowicz A, Styczynski G, Szulc M, Kurzyna M, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22: 649-53.
- Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, et al. Usefulness of Bedside Testing for Brain Natriuretic Peptide to Identify Right Ventricular Dysfunction and Outcome in Normotensive Patients With Acute Pulmonary Embolism. Am J Cardiol 2006; 97: 1386-90.
- Tulevski II, Hirsch A, Sanson BJ, Romkes H, Van der Wall EE, Van Veldhuisen DJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001; 86: 1193-6.
- Kostrubiec M et al, Biomarker-based risk assessment model in acute pulmonary embolism , Eur Heart J 2005; 26(20): 2166-72. Epub 2005 May 23.
- Meyer T; Binder L; Hruska N; Luthe H; Buchwald AB, Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36(5): 1632-6.
- Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponin I and T in risk stratification of patients with acutepulmonary embolism. Circulation 2002; 106: 1263-8.
- Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis.Circulation 2007; 116: 427-33.
- Meyer T, Binder L, Hruska N, et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36: 1632-6.
- Shokoohi H, et al. The correlation between elevated cardiac troponin I and pulmonary artery obstruction index in ED patients with pulmonary embolism, American Journal of Emergency Medicine 2009; 27: 449-53.
- ADouketis JD, Crowther MA, Stanton EB, Ginsberg JS. Elevated cardiac troponin levels in patients with submassive pulmonary embolism Arch Intern Med 2002; 162(1): 79-88.
- Ersin A, Sedat Y, Selahattin K. Can elevated troponin I levels predict complicated clinical course and inhospital mortality in patients with acute pulmonary embolism? American Journal of Emergency Medicine 2007; 25: 138-43.
- Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia. A preliminary report. J Emerg Med 2000; 19: 311-5.
- Suleyman T, Abdulkadir G, Ahmet M, Suleyman C, Sennur E, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. American Journal of Emergency Medicine 2007; 25: 770-3.
- Stein PD, Hull RD, Patel KC, Olson RE, GhaliWA, Brant R, etal. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004; 140: 589-602.
- Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost 2007; 5: 296-304.
- Grau E, Tenías J M, Soto M J, Gutierrez, M R. dimer levels correlate with mortality in patient with acute pulmonary embolism. Critical Care Medicine 2007; 35(8): 1937-41.
- Kostrubiec M, Pruszczyk P, Bochowicz A, Pacho R, Szulc M,Kaczynska A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-72.
- Kucher N, Wallmann D, Carone A, Windecker S, Meier B, Hess OM. Incremental prognostic value of troponin I and echocardiography in patients with acute pulmonary embolism. Eur Heart J 2003; 24: 1651-6